{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:56:28Z","timestamp":1774421788666,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Context:<\/jats:title>\n            <jats:p>Targeted identification and treatment of people with latent tuberculosis infection (LTBI) are key components of the US tuberculosis elimination strategy. Because of recent policy changes, some LTBI treatment may shift from public health departments to the private sector.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To (1) develop methodology to estimate initiation and completion of treatment with isoniazid for LTBI using claims data, and (2) estimate treatment completion rates for isoniazid regimens from commercial insurance claims.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Medical and pharmacy claims data representing insurance-paid services rendered and prescriptions filled between January 2011 and March 2015 were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Participants:<\/jats:title>\n            <jats:p>Four million commercially insured individuals 0 to 64 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main Outcome Measures:<\/jats:title>\n            <jats:p>Six-month and 9-month treatment completion rates for isoniazid LTBI regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There was an annual isoniazid LTBI treatment initiation rate of 12.5\/100 000 insured persons. Of 1074 unique courses of treatment with isoniazid for which treatment completion could be assessed, almost half (46.3%; confidence interval, 43.3-49.3) completed 6 or more months of therapy. Of those, approximately half (48.9%; confidence interval, 44.5-53.3) completed 9 months or more.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Claims data can be used to identify and evaluate LTBI treatment with isoniazid occurring in the commercial sector. Completion rates were in the range of those found in public health settings. These findings suggest that the commercial sector may be a valuable adjunct to more traditional venues for tuberculosis prevention. In addition, these newly developed claims-based methods offer a means to gain important insights and open new avenues to monitor, evaluate, and coordinate tuberculosis prevention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/phh.0000000000000628","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T17:54:29Z","timestamp":1509126869000},"page":"E25-E33","source":"Crossref","is-referenced-by-count":10,"title":["Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured"],"prefix":"10.1097","volume":"24","author":[{"given":"Erica L.","family":"Stockbridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thaddeus L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"16","key":"R1-20230929","first-page":"269","article-title":"A strategic plan for the elimination of tuberculosis in the United States","volume":"38","year":"1989","journal-title":"MMWR Suppl"},{"issue":"RR-9","key":"R2-20230929","first-page":"1","article-title":"Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET)","volume":"48","year":"1999","journal-title":"MMWR Recomm Rep"},{"issue":"11","key":"R4-20230929","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15585\/mmwr.mm6511a2","article-title":"Leveling of tuberculosis incidence\u2014United States, 2013-2015","volume":"65","author":"Salinas","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"R5-20230929","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"R6-20230929","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"R7-20230929","doi-asserted-by":"crossref","first-page":"e0153728","DOI":"10.1371\/journal.pone.0153728","article-title":"Recent transmission of tuberculosis\u2014United States, 2011-2014","volume":"11","author":"Yuen","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"R8-20230929","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"R10-20230929","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1164\/rccm.200510-1563OC","article-title":"The scope and impact of treatment of latent tuberculosis infection in the United States and Canada","volume":"173","author":"Sterling","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"R11-20230929","doi-asserted-by":"crossref","first-page":"e110645","DOI":"10.1371\/journal.pone.0110645","article-title":"Tuberculosis treatment managed by providers outside the public health department: lessons for the Affordable Care Act","volume":"9","author":"Ehman","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"R12-20230929","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/003335491513000413","article-title":"Tuberculosis elimination efforts in the United States in the era of insurance expansion and the Affordable Care Act","volume":"130","author":"Balaban","year":"2015","journal-title":"Public Health Rep"},{"issue":"9","key":"R14-20230929","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"R16-20230929","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"issue":"2","key":"R19-20230929","first-page":"95","article-title":"Recent trends in the dispensing of 90-day-supply prescriptions at retail pharmacies: implications for improved convenience and access","volume":"4","author":"Liberman","year":"2011","journal-title":"Am Health Drug Benefits"},{"issue":"11","key":"R20-20230929","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB Trial in the United States and Canada","volume":"62","author":"Moro","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"R22-20230929","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"R23-20230929","first-page":"CD005029","article-title":"Treatment for ataxia in multiple sclerosis","author":"Mills","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"R24-20230929","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"Sandgren","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"50-51","key":"R25-20230929","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.15585\/mmwr.mm6450a1","article-title":"Tuberculosis contact investigations\u2014United States, 2003-2012","volume":"64","author":"Young","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"R26-20230929","doi-asserted-by":"crossref","first-page":"e000532","DOI":"10.1161\/JAHA.113.000532","article-title":"Prospective relationship of change in ideal cardiovascular health status and arterial stiffness: the Cardiovascular Risk in Young Finns Study","volume":"3","author":"Aatola","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"R27-20230929","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"issue":"13","key":"R28-20230929","doi-asserted-by":"crossref","first-page":"824","DOI":"10.12968\/bjon.2011.20.13.824","article-title":"Latent tuberculosis: concordance and duration of treatment regimens","volume":"20","author":"Clerk","year":"2011","journal-title":"Br J Nurs"},{"issue":"3","key":"R29-20230929","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1503\/cmaj.091824","article-title":"Adverse events associated with treatment of latent tuberculosis in the general population","volume":"183","author":"Smith","year":"2011","journal-title":"CMAJ"},{"issue":"6","key":"R30-20230929","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"R31-20230929","first-page":"w13240","article-title":"Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis","volume":"141","author":"Fresard","year":"2011","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"R32-20230929","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1183\/09031936.00034007","article-title":"Patient choice promotes adherence in preventive treatment for latent tuberculosis","volume":"30","author":"Rennie","year":"2007","journal-title":"Eur Respir J"},{"issue":"3","key":"R33-20230929","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1086\/600394","article-title":"A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts","volume":"49","author":"Young","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R34-20230929","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1086\/314037","article-title":"Treatment of latent tuberculosis infection in patients aged > or = 35 years","volume":"31","author":"Gilroy","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R35-20230929","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2006.04.010","article-title":"Predictors of failure to complete treatment for latent tuberculosis infection","volume":"54","author":"Parsyan","year":"2007","journal-title":"J Infect"},{"issue":"4","key":"R36-20230929","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"R38-20230929","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.300.4.405","article-title":"Tuberculosis among foreign-born persons in the United States","volume":"300","author":"Cain","year":"2008","journal-title":"JAMA"},{"issue":"6","key":"R40-20230929","first-page":"e379","article-title":"Medication adherence and measures of health plan quality","volume":"21","author":"Seabury","year":"2015","journal-title":"Am J Manag Care"},{"issue":"1","key":"R43-20230929","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.publhealth.22.1.213","article-title":"Administrative data for public health surveillance and planning","volume":"22","author":"Virnig","year":"2001","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"R50-20230929","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11096-013-9872-y","article-title":"Interventions aimed at improving performance on medication adherence metrics","volume":"36","author":"McGinnis","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"R51-20230929","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy","volume":"40","author":"O'Malley","year":"2005","journal-title":"Health Serv Res"}],"container-title":["Journal of Public Health Management and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00124784-201807000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:35:06Z","timestamp":1695969306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124784-201807000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/phh.0000000000000628","relation":{},"ISSN":["1078-4659"],"issn-type":[{"value":"1078-4659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}